Shearman & Sterling advised BioLexis Pte. Limited (formerly known as “GMS Tenshi Holdings Pte. Limited”) in connection with its purchase, in a private placement, of up to an additional $20 million of the common stock of Oncobiologics. This investment is BioLexis’ third investment in Oncobiologics. The private placement is expected to close in four tranches, subject to customary closing conditions and achievement of certain funding milestones, including the amendment of BioLexis’ senior secured notes.